IRA impact on biopharma: Latest disclosures range from unknown to negative
Drugmakers are attempting to detail how they expect Medicare’s drug price “negotiations” (a term now co-opted by the biopharma industry as “price setting”) to impact their businesses as CMS begins to lay out pricing rules for a small subset of the highest spending single-source drugs and biologics reimbursed under Medicare Part B and Part D.
The initial “sky is falling” attitude from the biopharma industry has been tempered with more understanding of what’s coming, and even Novartis CEO Vas Narasimhan pointed to its breast cancer drug Kisqali as a likely target for CMS negotiations near the end of this decade.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters